Stage III ovarian cancer represents a significant medical challenge where cancer has spread beyond the pelvis into the abdominal cavity or lymph nodes, requiring a combination of surgical and medical approaches to control the disease and improve patients’ quality of life.

Understanding Treatment Goals for Advanced Ovarian Cancer

When ovarian cancer reaches stage III, the disease has moved beyond its original location in the ovaries or fallopian tubes and has spread to the lining of the abdomen, called the peritoneum, or to nearby lymph nodes. At this stage, treatment aims to remove as much cancer as possible through surgery and destroy remaining cancer cells with medication. The main goals include controlling the disease, extending survival, managing symptoms, and maintaining the best possible quality of life for patients.

Treatment decisions depend on several important factors. Doctors consider where exactly the cancer has spread, whether a specialized surgeon believes all visible cancer can be removed, and the patient’s overall health condition. About 60 percent of people with ovarian cancer are diagnosed at stage III, making it the most common stage at diagnosis. This means that medical teams have substantial experience treating this stage of disease.

The approach to treating stage III ovarian cancer has evolved significantly over recent decades. While complete cure may not always be possible, many treatment options exist that can significantly extend life and reduce symptoms. Some patients respond so well to treatment that they can live for many years after diagnosis. Medical societies have established standard treatment guidelines, and researchers continue to test new therapies in clinical trials to find even better ways to treat this disease.

Standard Treatment Approaches

The cornerstone of standard treatment for stage III ovarian cancer combines surgery with chemotherapy. Most patients undergo surgery first, though in some cases chemotherapy may be given before surgery to shrink the cancer and make it easier to remove.

Surgical Treatment

Surgery for stage III ovarian cancer is performed by a specialized surgeon called a gynaecological oncologist. The surgical procedure aims to remove both ovaries, both fallopian tubes, the uterus including the cervix, and as much visible cancer as possible. This type of surgery is called cytoreductive surgery or debulking surgery. The surgeon also checks the pelvis and abdomen to see where cancer has spread and may take tissue samples from lymph nodes to determine if cancer cells are present there.

The extent of surgery depends on where the cancer has spread. Surgeons may need to remove fatty tissue from the upper abdomen, called the omentum, or portions of other organs where cancer has grown, such as parts of the intestines, liver, or bladder. The goal is to leave behind no visible cancer or the smallest amount possible, as this greatly improves the chances that chemotherapy will be effective.

During surgery, doctors also perform what is called surgical staging. They collect tissue samples from different areas and rinse the abdomen with salt water, collecting this fluid for laboratory analysis. This helps determine exactly how far the cancer has spread and guides decisions about which chemotherapy drugs to use and for how long.

Chemotherapy Treatment

Chemotherapy uses powerful drugs to destroy cancer cells throughout the body. For stage III ovarian cancer, chemotherapy is typically given using a combination of two or more drugs. The most common combination pairs a platinum drug (such as carboplatin or cisplatin) with a taxane drug (such as paclitaxel or docetaxel). Carboplatin combined with paclitaxel is the most frequently used regimen and is delivered directly into a vein, called intravenous or IV chemotherapy.

The timing of chemotherapy varies depending on individual circumstances. Many patients receive adjuvant chemotherapy, which means chemotherapy given after surgery to destroy any remaining cancer cells and reduce the risk of the cancer returning. Chemotherapy may be given every few weeks for several months, typically involving three to six treatment cycles.

Some patients receive neoadjuvant chemotherapy, which is chemotherapy given before surgery. This approach is used when doctors believe the cancer is too widespread to remove completely at first, or when a patient is not healthy enough for immediate major surgery. After several rounds of chemotherapy shrink the cancer, the patient undergoes interval cytoreductive surgery, followed by additional chemotherapy afterward.

A specialized type of chemotherapy called hyperthermic intraperitoneal chemotherapy, or HIPEC, involves delivering heated chemotherapy drugs directly into the abdomen during surgery. This allows higher concentrations of drugs to reach cancer cells in the peritoneum while limiting exposure to the rest of the body. Not all patients are candidates for HIPEC, and it is typically offered at specialized centers with expertise in this technique.

Targeted Cancer Drugs

In addition to traditional chemotherapy, some patients may receive targeted cancer drugs that work differently from standard chemotherapy. These drugs attack specific features of cancer cells. One example is bevacizumab (brand name Avastin), which blocks the growth of new blood vessels that tumors need to grow. Bevacizumab may be given along with chemotherapy and then continued on its own for up to a year or longer.

Another group of targeted drugs called PARP inhibitors may be offered to patients whose genetic testing reveals certain mutations, particularly in genes called BRCA1 or BRCA2. These drugs help prevent cancer cells from repairing their damaged DNA, causing the cancer cells to die. PARP inhibitors are given as pills and may be continued for about two years after chemotherapy to help keep the cancer in remission.

Side Effects of Standard Treatment

Surgery for ovarian cancer is major surgery and requires several weeks of recovery. Patients may experience pain, fatigue, and changes in bowel function. Some women experience bowel obstruction, a serious complication where the intestines become blocked, causing nausea, vomiting, and inability to have bowel movements. Doctors provide individualized bowel regimens including stool softeners to help manage these issues.

Chemotherapy causes side effects that vary from person to person. Common short-term effects include nausea, vomiting, loss of appetite, fatigue, and muscle or joint aches. Many patients experience peripheral neuropathy, which is numbness and tingling in the fingers and toes caused by nerve damage from chemotherapy drugs. Hair loss is common but temporary. Chemotherapy weakens the immune system, making patients more susceptible to infections.

Some side effects persist long-term. Peripheral neuropathy can be permanent in some patients. Bowel and bladder function may take up to a year to return to normal. Many patients experience “chemo brain,” which refers to problems with memory, concentration, and thinking clearly. This can last for months after treatment ends. Fatigue often persists for many months, and it takes approximately a full year for most patients to recover their usual energy levels after completing chemotherapy.

When Surgery Is Not Possible

If cancer has spread too widely or a patient is too unwell for surgery, chemotherapy alone may be used to shrink the cancer as much as possible and slow its growth. Additional treatments can help relieve symptoms. For example, if fluid accumulates in the abdomen (called ascites), this can be drained to reduce discomfort and difficulty breathing. If cancer causes bowel blockage, procedures or medications can help manage this. Radiation therapy may be used to relieve pain or other symptoms in specific areas.

Treatment in Clinical Trials

Clinical trials are research studies that test promising new treatments before they become widely available. For stage III ovarian cancer, many clinical trials are underway exploring innovative approaches that may improve outcomes beyond what standard treatment offers. Participating in a clinical trial gives patients access to cutting-edge therapies while contributing to medical knowledge that will help future patients.

Understanding Clinical Trial Phases

Clinical trials for cancer drugs proceed through several phases. Phase I trials test a new drug or treatment approach in a small number of people to evaluate its safety, determine appropriate doses, and identify side effects. Phase II trials involve more patients and focus on whether the treatment is effective against the cancer while continuing to monitor safety. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to see which approach works better or has fewer side effects.

Immunotherapy Approaches

Immunotherapy treatments help the body’s own immune system recognize and attack cancer cells. Several types of immunotherapy are being tested for ovarian cancer in clinical trials. These include drugs called checkpoint inhibitors that remove the brakes from immune cells, allowing them to attack cancer more effectively. Examples include pembrolizumab and nivolumab, which target proteins called PD-1 or PD-L1 that cancer cells use to hide from the immune system.

Some trials are testing cancer vaccines designed to train the immune system to recognize specific proteins found on ovarian cancer cells. Other approaches use patients’ own immune cells, which are removed from the body, modified or multiplied in the laboratory, and then returned to the patient to fight the cancer. While these therapies have shown promise in other cancers, researchers are working to determine how best to use them for ovarian cancer.

Novel Targeted Therapies

Beyond the PARP inhibitors already used in standard treatment, researchers are testing many other targeted drugs in clinical trials. Some target specific mutations or proteins found in ovarian cancer cells. Others block signals that cancer cells use to grow and spread. For example, drugs targeting proteins called tyrosine kinases or molecules involved in cell growth pathways are being studied.

Combination approaches are also being explored, such as using two different targeted drugs together, or combining targeted drugs with chemotherapy or immunotherapy. The goal is to attack cancer cells through multiple mechanisms simultaneously, making it harder for the cancer to develop resistance to treatment.

Innovative Surgical Techniques

Clinical trials are also testing refinements to surgical techniques. Some studies are evaluating whether performing surgery in specific ways or at specific times during treatment leads to better outcomes. Others are exploring the use of advanced imaging techniques during surgery to help surgeons identify and remove all cancer tissue more effectively.

Intraperitoneal Treatment Approaches

Building on the concept of HIPEC, researchers are testing various ways to deliver drugs directly into the abdomen. Some trials evaluate giving standard chemotherapy drugs into the peritoneal cavity instead of through the veins, which allows higher drug concentrations to reach cancer cells in the abdomen. Other studies test immunotherapy drugs or targeted drugs delivered this way, either during surgery or through a catheter afterward.

Trial Locations and Eligibility

Clinical trials for ovarian cancer are conducted at cancer centers and research hospitals throughout the world, including in Europe, the United States, and many other countries. Each trial has specific eligibility criteria based on factors such as cancer stage, previous treatments received, overall health, and sometimes specific genetic features of the cancer. Your doctor can help you determine whether you might be eligible for any clinical trials and can assist in the enrollment process.

Participation in clinical trials is voluntary, and patients can withdraw at any time. Trials typically provide the experimental treatment at no cost, though other medical expenses may still apply. Before joining a trial, you will receive detailed information about what the study involves, potential risks and benefits, and what will be expected of you.

Most common treatment methods

• Surgery (Cytoreductive/Debulking Surgery)
  • Removal of both ovaries, fallopian tubes, uterus, and cervix
  • Removal of visible cancer throughout the pelvis and abdomen
  • May include removal of omentum, parts of intestines, or portions of other affected organs
  • Surgical staging through tissue sampling and collection of peritoneal washings
  • Interval cytoreductive surgery performed after neoadjuvant chemotherapy
• Intravenous Chemotherapy
  • Carboplatin combined with paclitaxel as the most common regimen
  • Alternative platinum drugs include cisplatin
  • Alternative taxane drugs include docetaxel
  • Given as adjuvant therapy after surgery or neoadjuvant therapy before surgery
  • Typically administered in cycles every few weeks for several months
• Intraperitoneal Chemotherapy
  • Hyperthermic intraperitoneal chemotherapy (HIPEC) delivered during surgery
  • Heated chemotherapy drugs applied directly to abdominal cavity
  • Allows higher drug concentrations at tumor sites
  • Available at specialized cancer centers
• Targeted Therapy
  • Bevacizumab (Avastin) blocks blood vessel growth to tumors
  • Given with chemotherapy and continued as maintenance therapy
  • PARP inhibitors for patients with BRCA mutations
  • Taken as maintenance therapy for up to two years
  • Helps prevent cancer recurrence
• Supportive and Palliative Treatments
  • Drainage of abdominal fluid (ascites)
  • Management of bowel obstruction
  • Radiation therapy for pain relief
  • Medications to control symptoms and side effects